One Of Pharma's Biggest Enemies Goes After The Future's Best-Selling Drug
Matthew Herper
Forbes Staff
Getting a drug company to cut its price is harder than it sounds. Haines spoke on a conference call with ISI clients Friday about Waxman’s probable intent of embarrassing regulators. The Food and Drug Administration rushed to approve Sovaldi, the argument goes, and then Gilead goes and charges $84,000 per patient?
And Gilead, when it’s already going to be bringing in billions of dollars a quarter, would be foolish to simply back down, not matter how intense the criticism....
Except that the stakes here are actually even higher. Sovaldi is a potent drug by itself, but the real excitement is about using it as part of an all-oral single-pill combination that would cure hepatitis C patients without interferon and ribavirin. Analysts have speculated that such a pill could cost $100,000 per patient.
Continue reading @ Forbes
No comments:
Post a Comment